Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2008

View Archived Issues

Adjunctive topiramate decreases compulsions in obsessive-compulsive disorder

Levetiracetam shows promise in body dysmorphic disorder

Studies evaluate prevention of post-stroke depression, PTSD with escitalopram

Promising results with antisense oligonucleotide PRO-051 in Duchenne's muscular dystrophy

Positive data reported for Acambis' ACAM-FLU-A influenza vaccine

Positive results found in QuatRx's pivotal postmenopausal vaginal syndrome study

GSK and Theravance initiate phase IIb ICS and LABA studies for asthma

FDA accepts IND application for EntreMed's Aurora kinase/angiogenesis inhibitor

DOR BioPharma's oral BDP designated orphan drug in pediatric Crohn's disease

Novel mineralocorticoid receptor antagonists emerge from Bayer R&D

Recent Roche patent describes new cognition enhancers for Alzheimer's disease

Allergan patents novel antiglaucoma agents

New oncolytic drugs imparted in recent patents

Daiichi Sankyo and Lilly submit NDA to FDA for oral antiplatelet agent prasugrel

Genmab initiates HuMax-CD32b preclinical program for IgG1,k antibody

FDA grants orphan drug designation to Ovation's clobazam for Lennox-Gastaut syndrome

Kosan initiates TIME-1 phase III clinical trial of tanespimycin for multiple myeloma

EMEA agrees with Spectrum's clinical development plan for phase III trials of EOquin

Millennium presents an update on Velcade, MLN-0002, MLN-4924 and MLN-2238

Infinity and MedImmune initiate phase Ib clinical trial of IPI-504 with Taxotere

MethylGene files IND application with the FDA for c-MET inhibitor MGCD-265

Protox reports positive final results from phase I study of PRX-302 for BPH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...